伊伐布雷定对慢性心力衰竭的治疗效果  

The efficacy of Ivabradine in the treatment of patients with chronic heart failure

作　　者：王爱秋[1] 杨光全[2] 闫世冉 WANG Aiqiu;YANG Guangquan;YAN Shiran(Heze Disease Prevention and Control Center;Heze Municipal Hospital,Heze 274000,Shandong)

机构地区：[1]菏泽市疾病预防控制中心 [2]菏泽市立医院,山东菏泽274000

出　　处：《菏泽医学专科学校学报》2019年第2期30-32,共3页Journal of Heze Medical College

摘　　要：目的探讨伊伐布雷定对慢性心力衰竭患者心功能和心肌损伤的影响。方法选取慢性心力衰竭患者68例,按照随机数表法分为观察组和对照组。对照组33例采用心力衰竭标准治疗方案治疗[1],即螺内酯、β受体阻滞剂、利尿剂和ACEI/ARB类药物;观察组35例在此基础上加用常规剂量的伊伐布雷定。观察两组患者在治疗前后N末端脑钠肽前体(NT-proBNP)水平以及左室射血分数(LVEF)、每搏心输出量(SV)等情况。结果治疗1周后,两组疗效比较,P<0.05;两组的NT-proBNP水平、LVEF、SV在治疗前后均有明显变化,P<0.05,观察组NT-proBNP水平及SV变化与对照组比较,P<0.05。结论在慢性心力衰竭患者标准治疗方案的基础上联用常规剂量的伊伐布雷定能够显著改善心脏收缩能力,减轻心肌损伤,疗效显著,值得积极推广。Objective To explore the effect of ivabradine on cardiac function and myocardial injury of patients with chronic heart failure.Methods 68 patients with chronic heart failure admitted into Heze municipal hospital were enrolled in this study and randomly divided into the observation group (35 cases) and the control group (33 cases).The control group was treated with standard anti-heart failure drugs,such as spironolactone,β receptor blockers,diuretics and ACEI/ ARB drugs and the observation group was treated with ivabradine on the basis of the control group.The NT-proBNP level, LVEF,SV were compared between the two groups.Results After the treatment,there was a significant difference in the total effective rate between the observation group and the control group (P<0.05).The levels of NT-proBNP,LVEF and SV had significant difference before and after treatment in the two groups (P<0.05).The levels of NT-proBNP and SV in observation group were significantly different from those in the control group (P<0.05).The efficacy of the two groups was comapred with P<0.05.Conclusion Ivabradine combined with standard treatment for heart failure can significantly improve cardiac contractility and reduce myocardial injury.

关 键 词：伊伐布雷定 慢性心力衰竭 N末端脑钠肽前体 

分 类 号：R541.6[医药卫生—心血管疾病]